TABLE 1.
Overall (n = 407) | AFP > 1,000 → ≤ 100 ng/mL (n = 58) | AFP > 1,000 → 101-499 ng/mL (n = 39) | AFP > 1,000 → 500-1,000 ng/mL (n = 17) | AFP > 1,000 ng/mL (n = 293) | P Value | |
---|---|---|---|---|---|---|
Age (IQR) | 56 (52-61) | 60 (54-63) | 56 (47-61) | 57 (53-60) | 56 (52-60) | 0.01 |
Male (%) | 290 (70.5) | 38 (65.5) | 22 (56.4) | 15 (88.2) | 215 (73.4) | 0.04 |
Ethnicity (%) | 0.44 | |||||
Caucasian | 238 (58.5) | 29 (50.0) | 24 (61.5) | 10 (58.8) | 175 (59.7) | |
Asian | 58 (14.3) | 16 (27.6) | 5 (12.8) | 3 (17.6) | 34 (11.6) | |
Hispanic | 52 (12.8) | 6 (10.3) | 4 (10.3) | 2 (11.8) | 40 (13.7) | |
Black | 49 (12.0) | 6 (10.3) | 5 (12.8) | 1 (5.9) | 37 (12.6) | |
Other | 10 (2.5) | 1 (1.7) | 1(2.6) | 1 (5.9) | 7 (2.4) | |
Cause (%) | 0.009 | |||||
HCV | 249 (61.2) | 31 (53.4) | 22 (56.4) | 14 (82.3) | 182 (62.1) | |
HBV | 42 (10.3) | 12 (20.7) | 1 (2.6) | 1 (5.9) | 28 (9.6) | |
Alcohol | 16 (3.9) | 0 | 1 (2.6) | 0 | 15 (5.1) | |
Autoimmune* | 10 (2.5) | 0 | 4 (10.3) | 0 | 6 (2.0) | |
NASH | 8 (2.0) | 1 (1.7) | 1 (2.6) | 1 (5.9) | 5 (1.7) | |
Other | 82 (20.1) | 14 (24.1) | 10 (25.6) | 1 (5.9) | 57 (19.5) | |
MELD-Na (IQR) | 10 (8-15) | 9 (7-11) | 9 (7-13) | 10 (8-15) | 11 (8-16) | 0.004 |
Child class (%)† | 0.07 | |||||
A | 149 (36.7) | 27 (46.6) | 18 (46.2) | 8 (47.1) | 96 (32.9) | |
B | 189 (46.6) | 25 (43.1) | 19 (48.7) | 5 (29.4) | 140 (47.9) | |
C | 68 (16.7) | 6 (10.3) | 2 (5.1) | 4 (23.5) | 56 (19.2) | |
Initial tumor stage (%) | 0.49 | |||||
Milan | 381 (93.6) | 56 (96.6) | 38 (97.4) | 16 (94.1) | 271 (92.5) | |
UCSF down-staging‡ | 26 (6.4) | 2 (3.4) | 1 (2.6) | 1 (5.9) | 22 (7.5) | |
Total tumor diameter (cm) (IQR) | 3.0 (2.3-4.2) | 2.7 (2.2-3.5) | 3.0 (2.2-4.4) | 2.3 (2.0-2.8) | 3.2 (2.3-4.3) | 0.03 |
Includes autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cholangitis.
n= 406.
One lesion > 5 and ≤ 8 cm; 2-3 lesions, with at least one being > 3 cm and ≤ 5 cm and having total tumor diameter ≤ 8 cm; or 4-5 lesions, each ≤ 3 cm with total tumor diameter ≤ 8 cm.